Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction ( VICTORIA ) trial
Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.AIMSWhether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.We studied 488...
Saved in:
Published in | European journal of heart failure Vol. 25; no. 10; pp. 1822 - 1830 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.10.2023
|
Online Access | Get full text |
Cover
Loading…
Abstract | Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.AIMSWhether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.We studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12-lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N-terminal pro-B-type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8 months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all-cause deaths. Median age was 68 years (interquartile range [IQR] 60-76), 24% were women, median ejection fraction was 30% (IQR 23-35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19-28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10 ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all-cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all-cause death (HR 1.44). The only sex-based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction = 0.024) and all-cause death (men: HR 0.99; women: HR 1.57; pinteraction = 0.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87-1.79; female: HR 2.50, 95% CI 1.23-5.06; pinteraction = 0.141).METHODS AND RESULTSWe studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12-lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N-terminal pro-B-type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8 months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all-cause deaths. Median age was 68 years (interquartile range [IQR] 60-76), 24% were women, median ejection fraction was 30% (IQR 23-35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19-28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10 ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all-cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all-cause death (HR 1.44). The only sex-based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction = 0.024) and all-cause death (men: HR 0.99; women: HR 1.57; pinteraction = 0.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87-1.79; female: HR 2.50, 95% CI 1.23-5.06; pinteraction = 0.141).Routine ECG measurements provide additional prognostication of mortality in high-risk HFrEF patients, particularly in women with contiguous pathologic Q waves.CONCLUSIONRoutine ECG measurements provide additional prognostication of mortality in high-risk HFrEF patients, particularly in women with contiguous pathologic Q waves. |
---|---|
AbstractList | Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.AIMSWhether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.We studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12-lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N-terminal pro-B-type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8 months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all-cause deaths. Median age was 68 years (interquartile range [IQR] 60-76), 24% were women, median ejection fraction was 30% (IQR 23-35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19-28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10 ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all-cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all-cause death (HR 1.44). The only sex-based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction = 0.024) and all-cause death (men: HR 0.99; women: HR 1.57; pinteraction = 0.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87-1.79; female: HR 2.50, 95% CI 1.23-5.06; pinteraction = 0.141).METHODS AND RESULTSWe studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12-lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N-terminal pro-B-type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8 months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all-cause deaths. Median age was 68 years (interquartile range [IQR] 60-76), 24% were women, median ejection fraction was 30% (IQR 23-35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19-28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10 ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all-cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all-cause death (HR 1.44). The only sex-based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction = 0.024) and all-cause death (men: HR 0.99; women: HR 1.57; pinteraction = 0.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87-1.79; female: HR 2.50, 95% CI 1.23-5.06; pinteraction = 0.141).Routine ECG measurements provide additional prognostication of mortality in high-risk HFrEF patients, particularly in women with contiguous pathologic Q waves.CONCLUSIONRoutine ECG measurements provide additional prognostication of mortality in high-risk HFrEF patients, particularly in women with contiguous pathologic Q waves. |
Author | Westerhout, Cynthia M. Armstrong, Paul W. O'Connor, Christopher Lam, Carolyn S.P. Ly, Eric Ponikowski, Piotr Roessig, Lothar Blaustein, Robert O. Temple, Tracy Yogasundaram, Haran Zheng, Yinggan Sandhu, Roopinder K. Ezekowitz, Justin |
Author_xml | – sequence: 1 givenname: Haran surname: Yogasundaram fullname: Yogasundaram, Haran organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada – sequence: 2 givenname: Yinggan surname: Zheng fullname: Zheng, Yinggan organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada – sequence: 3 givenname: Eric surname: Ly fullname: Ly, Eric organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada – sequence: 4 givenname: Justin surname: Ezekowitz fullname: Ezekowitz, Justin organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada – sequence: 5 givenname: Piotr surname: Ponikowski fullname: Ponikowski, Piotr organization: Institute of Heart Diseases, Wroclaw Medical University Wroclaw Poland – sequence: 6 givenname: Carolyn S.P. surname: Lam fullname: Lam, Carolyn S.P. organization: National Heart Centre Singapore, Singapore & Duke‐National University of Singapore Singapore Singapore – sequence: 7 givenname: Christopher surname: O'Connor fullname: O'Connor, Christopher organization: Inova Heart and Vascular Institute Falls Church VA USA – sequence: 8 givenname: Robert O. surname: Blaustein fullname: Blaustein, Robert O. organization: Merck & Co., Inc. Whippany NJ USA – sequence: 9 givenname: Lothar surname: Roessig fullname: Roessig, Lothar organization: Bayer AG Wuppertal Germany – sequence: 10 givenname: Tracy surname: Temple fullname: Temple, Tracy organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada – sequence: 11 givenname: Cynthia M. surname: Westerhout fullname: Westerhout, Cynthia M. organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada – sequence: 12 givenname: Paul W. surname: Armstrong fullname: Armstrong, Paul W. organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada – sequence: 13 givenname: Roopinder K. surname: Sandhu fullname: Sandhu, Roopinder K. organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada |
BookMark | eNptkcFO3DAQhqOKSgXaQ99gjnAI2I6TeHtDKxYiISEtW66R40w23iZxajtC3HiEPmNfoS9QZ8Op6skjzzefPP7PopPBDBhFXym5ooSwazy0zVVCGP0QnVKRr2IiOD8JdSJEvBKcfYrOnDsQQvOAn0Z_tthJr83gWj1Chf4FcYBKOuz0gIAdKm-NkrbWZm_l2GoFPUo3Wexx8A7kUIOZvDI9OtADjMF2bLxo30Kr9-3vt19Wux_QorQeGqm7MPwNisGFZgAba3rwLcIz2mKt95PcwV1nKtnBk5_q19n6NFWH8JJ36_3RtFlMy9UW60lhDbczFtaBjZVLcQHPxXr3uC1u4BK81bL7HH1sZOfwy_t5Hn3f3O7W9_HD412xvnmIFcuYj5MUOauruslSySue0zRjyBshmlyIPOUEeZXzNKWSKExXFSKvBa_YKnw7FUmWnEcXi3e05ueEzpe9dgq7Tg5oJlcykRFOUsZoQK8XVFnjnMWmVNofc_E2rFlSUs7xlnO85RxvmLj8Z2K0upf29T_sXwqerj8 |
CitedBy_id | crossref_primary_10_1002_ejhf_3070 crossref_primary_10_3389_fphar_2024_1359939 crossref_primary_10_1002_ejhf_3392 |
Cites_doi | 10.1016/j.jchf.2017.08.013 10.1136/hrt.2006.102319 10.1002/ejhf.561 10.1093/eurheartj/ehs337 10.1016/j.jacc.2018.08.1038 10.1161/01.hyp.25.2.242 10.1002/ejhf.2333 10.1161/01.cir.95.12.2660 10.1016/j.jacc.2008.12.015 10.1016/j.hrthm.2015.01.023 10.1056/NEJMoa1609758 10.1093/eurheartj/ehaa177 10.1016/j.jacc.2018.11.049 10.1007/s11739‐012‐0862‐1 10.1016/j.hrthm.2011.08.031 10.1016/j.jacc.2007.01.024 10.1016/j.amjmed.2015.11.035 10.1002/ejhf.2468 10.1161/CIRCULATIONAHA.105.584102 10.1016/j.ijcard.2009.08.005 10.1016/j.amjcard.2007.07.077 10.1253/circrep.CR‐19‐0025 10.1161/CIR.0b013e31829e8807 10.1161/CIRCHEARTFAILURE.123.010599 10.1093/eurheartj/ehi555 10.1161/CIRCULATIONAHA.108.191095 10.1016/j.jacc.2008.12.014 10.1001/jama.299.22.2656 10.1016/j.cardfail.2013.11.005 10.1007/s00392‐017‐1162‐6 10.1093/eurheartj/ehl259 10.1056/NEJMoa1401426 10.1016/j.ahj.2012.10.009 10.1111/j.1542‐474X.1997.tb00325.x 10.1056/NEJMoa1915928 10.1016/s0735‐1097(00)01102‐5 10.1093/europace/euw065 10.1016/j.amjcard.2010.11.010 10.1016/j.cardfail.2021.05.016 10.1016/j.cjca.2017.08.022 10.1093/eurheartj/ehz835 10.1002/ejhf.2285 10.1093/eurjhf/hfq002 10.1111/j.1542‐474X.2009.00345.x |
ContentType | Journal Article |
Copyright | 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. |
Copyright_xml | – notice: 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. |
CorporateAuthor | for the VICTORIA Study Group |
CorporateAuthor_xml | – name: for the VICTORIA Study Group |
DBID | AAYXX CITATION 7X8 |
DOI | 10.1002/ejhf.3021 |
DatabaseName | CrossRef MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-0844 |
EndPage | 1830 |
ExternalDocumentID | 10_1002_ejhf_3021 |
GroupedDBID | --- --K .I3 0R~ 1B1 1OC 1~5 29G 2WC 33P 4G. 53G 5GY 5VS 6PF 7-5 70D AAESR AAFWJ AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAPNW AASGY AAWTL AAXRX AAYCA AAYXX AAZKR ABCUV ABDBF ABJNI ABKDP ABLJU ABQWH ABXGK ABZBJ ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACRPL ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADEYI ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AENEX AEQDE AEUYR AEYWJ AFBPY AFFPM AFGKR AFWVQ AGHNM AGKEF AGQPQ AGYGG AHBTC AIACR AIJHB AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BRXPI C45 CITATION CKLRP CS3 CZ4 DCZOG DRFUL DRMAN DRSTM DU5 E3Z EBD EBS EJD EMOBN ESX F5P FEDTE FUBAC G-S GODZA H13 HGLYW HVGLF HZ~ IHE KBYEO LATKE LEEKS LITHE LOXES LUTES LYRES M41 MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N9A NQ- O0~ O66 O9- OK1 OVD O~Y P2P P2W Q1. RD5 RIG ROL RPZ RXO SDG SEL SEW SUPJJ SV3 TEORI TUS UHS V9Y W8F WBKPD WHWMO WIH WIJ WIK WIN WOHZO WVDHM WXSBR X7H ~91 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY |
ID | FETCH-LOGICAL-c262t-35e42dbdf65a4b471562e4f88f7887540e4b74551a0ce59bee4d84b2987918363 |
ISSN | 1388-9842 1879-0844 |
IngestDate | Fri Jul 11 08:12:09 EDT 2025 Tue Jul 01 01:54:30 EDT 2025 Thu Apr 24 23:08:27 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c262t-35e42dbdf65a4b471562e4f88f7887540e4b74551a0ce59bee4d84b2987918363 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PQID | 2860405221 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2860405221 crossref_citationtrail_10_1002_ejhf_3021 crossref_primary_10_1002_ejhf_3021 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-10-00 20231001 |
PublicationDateYYYYMMDD | 2023-10-01 |
PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-00 |
PublicationDecade | 2020 |
PublicationTitle | European journal of heart failure |
PublicationYear | 2023 |
References | e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_16_1 e_1_2_6_37_1 e_1_2_6_42_1 e_1_2_6_43_1 e_1_2_6_21_1 e_1_2_6_20_1 e_1_2_6_41_1 e_1_2_6_40_1 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_22_1 e_1_2_6_29_1 e_1_2_6_44_1 e_1_2_6_28_1 e_1_2_6_45_1 e_1_2_6_27_1 e_1_2_6_26_1 |
References_xml | – ident: e_1_2_6_20_1 doi: 10.1016/j.jchf.2017.08.013 – ident: e_1_2_6_6_1 doi: 10.1136/hrt.2006.102319 – ident: e_1_2_6_8_1 doi: 10.1002/ejhf.561 – ident: e_1_2_6_28_1 doi: 10.1093/eurheartj/ehs337 – ident: e_1_2_6_25_1 doi: 10.1016/j.jacc.2018.08.1038 – ident: e_1_2_6_44_1 doi: 10.1161/01.hyp.25.2.242 – ident: e_1_2_6_5_1 doi: 10.1002/ejhf.2333 – ident: e_1_2_6_15_1 doi: 10.1161/01.cir.95.12.2660 – ident: e_1_2_6_24_1 doi: 10.1016/j.jacc.2008.12.015 – ident: e_1_2_6_39_1 doi: 10.1016/j.hrthm.2015.01.023 – ident: e_1_2_6_13_1 doi: 10.1056/NEJMoa1609758 – ident: e_1_2_6_18_1 doi: 10.1093/eurheartj/ehaa177 – ident: e_1_2_6_2_1 doi: 10.1016/j.jacc.2018.11.049 – ident: e_1_2_6_9_1 doi: 10.1007/s11739‐012‐0862‐1 – ident: e_1_2_6_17_1 doi: 10.1016/j.hrthm.2011.08.031 – ident: e_1_2_6_21_1 doi: 10.1016/j.jacc.2007.01.024 – ident: e_1_2_6_32_1 doi: 10.1016/j.amjmed.2015.11.035 – ident: e_1_2_6_45_1 doi: 10.1002/ejhf.2468 – ident: e_1_2_6_14_1 doi: 10.1161/CIRCULATIONAHA.105.584102 – ident: e_1_2_6_16_1 doi: 10.1016/j.ijcard.2009.08.005 – ident: e_1_2_6_31_1 doi: 10.1016/j.amjcard.2007.07.077 – ident: e_1_2_6_41_1 doi: 10.1253/circrep.CR‐19‐0025 – ident: e_1_2_6_3_1 doi: 10.1161/CIR.0b013e31829e8807 – ident: e_1_2_6_29_1 doi: 10.1161/CIRCHEARTFAILURE.123.010599 – ident: e_1_2_6_34_1 doi: 10.1093/eurheartj/ehi555 – ident: e_1_2_6_23_1 doi: 10.1161/CIRCULATIONAHA.108.191095 – ident: e_1_2_6_27_1 doi: 10.1016/j.jacc.2008.12.014 – ident: e_1_2_6_37_1 doi: 10.1001/jama.299.22.2656 – ident: e_1_2_6_10_1 doi: 10.1016/j.cardfail.2013.11.005 – ident: e_1_2_6_12_1 doi: 10.1007/s00392‐017‐1162‐6 – ident: e_1_2_6_36_1 doi: 10.1093/eurheartj/ehl259 – ident: e_1_2_6_38_1 doi: 10.1056/NEJMoa1401426 – ident: e_1_2_6_11_1 doi: 10.1016/j.ahj.2012.10.009 – ident: e_1_2_6_26_1 doi: 10.1111/j.1542‐474X.1997.tb00325.x – ident: e_1_2_6_19_1 doi: 10.1056/NEJMoa1915928 – ident: e_1_2_6_40_1 doi: 10.1016/s0735‐1097(00)01102‐5 – ident: e_1_2_6_43_1 doi: 10.1093/europace/euw065 – ident: e_1_2_6_22_1 doi: 10.1016/j.amjcard.2010.11.010 – ident: e_1_2_6_33_1 doi: 10.1016/j.cardfail.2021.05.016 – ident: e_1_2_6_4_1 doi: 10.1016/j.cjca.2017.08.022 – ident: e_1_2_6_30_1 doi: 10.1093/eurheartj/ehz835 – ident: e_1_2_6_35_1 doi: 10.1002/ejhf.2285 – ident: e_1_2_6_7_1 doi: 10.1093/eurjhf/hfq002 – ident: e_1_2_6_42_1 doi: 10.1111/j.1542‐474X.2009.00345.x |
SSID | ssj0017002 |
Score | 2.4306529 |
Snippet | Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.AIMSWhether... |
SourceID | proquest crossref |
SourceType | Aggregation Database Enrichment Source Index Database |
StartPage | 1822 |
Title | Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction ( VICTORIA ) trial |
URI | https://www.proquest.com/docview/2860405221 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKroS4IJ5ieWlAHBZVWVLXdVJu3dLSon1Iq3S1cInycLotkKI2PdA_zZ0T41eSSkVauESRZY0szWfPjD3zDSFvPB99Yj_B2IRR5jAv6TjdxGs7ScQ4AkRyjMt7yNMzPpqwT1edq0bjdy1raV3ER8lmZ13J_2gVx1Cvskr2HzRbCsUB_Ef94hc1jN8b6bjMZKtnXEm7pHxH0-EmURmniph6ljS_V3eCmp15sS5waUKnk2uSVVPxJpmMHZV6LrteF80smskcdnmHMM5XMqhfVdUpl2I57s-m6yhofjQcI4quGqXi2TRXOSNK6kjJGmpZeuhC0sei4zuYC924fLg0HczR_b0c94Pzi3FPXl-oFiN_fUswfvXWYqtDbRqpWsSl3gAj_Cm3xZdroU-8z2jHp7UkpZ_WUpRxx0Z8XeCaN7qgZWV5y821Ca0S8OxJ73tdSWqrbzPEjjFjHnRdtt0Gbu2wx9CM7rRCmtVWzK-zo7arC8C3mb7PzsPh5OQkDAZXwS2yTzHEwTN6v3f84XhYvoF5rs6YtYuyvFgufVeK3vamtp0J5SEF98hdE9pAT-P0PmmI_AG5fWqSNx6SX3W4goErWLjCLrhCHa6AcAULV5jlYOEKEkVQwhUUAsAg4D1YsIIEKyBYoQIraLCCAquUacGqZSqwggGrHjJgBQtWsGCFQwvVt6CA-ohMhoOgP3JMvxEnoZwWTrsjGE3jNOOdiMXotWFsIFjm-5lMucXQRrDYYxhiRK4sXoyFYKnPYtpFDaFl5O3HZC9f5OIJAZ52Whlv85i6KUs5j7PMF27Wle_QrSgSB-TQ6i1MDBm_7AnzLdQ04jSUKg6lig_I63LqD81As2vSK6v8EO2DfPSLcrFYr0Lqc7TTGGW1nt5gzjNyp9osz8lesVyLF-h1F_FLA88_WirnDA |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+between+baseline+electrocardiographic+measurements+and+outcomes+in+patients+with+high-risk+heart+failure%3A+Insights+from+the+VerICiguaT+Global+Study+in+Subjects+with+Heart+Failure+with+Reduced+Ejection+Fraction+%28VICTORIA%29+trial&rft.jtitle=European+journal+of+heart+failure&rft.au=Yogasundaram%2C+Haran&rft.au=Zheng%2C+Yinggan&rft.au=Ly%2C+Eric&rft.au=Ezekowitz%2C+Justin&rft.date=2023-10-01&rft.issn=1879-0844&rft.eissn=1879-0844&rft.volume=25&rft.issue=10&rft.spage=1822&rft_id=info:doi/10.1002%2Fejhf.3021&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1388-9842&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1388-9842&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1388-9842&client=summon |